MG1111

MG1111 is a live attenuated varicella vaccine developed by GC Biopharma (formerly Green Cross Corporation) for the prevention of chickenpox (varicella) caused by the varicella-zoster virus (VZV). As a second-generation vaccine following the company's earlier Suduvax, MG1111 was designed to improve upon the safety and immunogenicity profile of existing varicella vaccines. It contains the Oka strain of the virus, which has been weakened through serial passage in cell culture to induce a robust immune response, including both humoral (antibody) and cell-mediated immunity, without causing clinical disease in healthy individuals. MG1111, marketed under the brand name Barycelva, has demonstrated non-inferiority to established vaccines like Varivax in clinical trials and received WHO prequalification in 2023, facilitating its use in global immunization programs.

Brand names

Barycelva

Other names

Live attenuated varicella vaccineGC Biopharma varicella vaccine